Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CNSP
stocks logo

CNSP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-5.090
-98.86%
--
--
-7.610
-59.86%
--
--
-1.240
-80.69%
Estimates Revision
The market is revising No Change the revenue expectations for CNS Pharmaceuticals, Inc. (CNSP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.17%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+5.17%
In Past 3 Month
Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.510
sliders
Low
20.00
Averages
20.00
High
20.00
Current: 6.510
sliders
Low
20.00
Averages
20.00
High
20.00
Maxim
Hold
to
Buy
upgrade
$20
2025-09-12
Reason
Maxim
Price Target
$20
2025-09-12
upgrade
Hold
to
Buy
Reason
Maxim upgraded CNS Pharmaceuticals to Buy from Hold with a $20 price target.
Maxim
Hold
to
Buy
upgrade
$20
2025-09-12
Reason
Maxim
Price Target
$20
2025-09-12
upgrade
Hold
to
Buy
Reason
As previously reported, Maxim upgraded CNS Pharmaceuticals to Buy from Hold with a $20 price target. The company has pivoted to its oncology asset TPI-287, a blood brain barrier crossing taxane in development initially for recurrent glioblastoma, the analyst tells investors in a research note. Maxim further cites CNS Pharma's road map for TPI-287, as well as a potential path forward with Berubicin and cash runway into the second half of 2026, as positioning the stock toward a recovery.
Alliance Global Partners
James Molloy
Buy
maintain
$4 -> $7
2025-05-22
Reason
Alliance Global Partners
James Molloy
Price Target
$4 -> $7
2025-05-22
maintain
Buy
Reason
Alliance Global Partners analyst James Molloy raised the firm's price target on CNS Pharmaceuticals to $7 from $4 pre-reverse-split and keeps a Buy rating on the shares after the company announced Q1 results and a quarterly update last week. The company recently pivoted to focusing on its TPI-287 candidate for Glioblastoma Multiforme after its lead candidate berubicin failed to meet the primary endpoint of a pivotal Phase 2 trial, notes the analyst, who is removing berubicin from the firm's valuation. The firm, which notes that CNS executed a 50:1 reverse split in Q1, values TPI-287 at $5.25 per share and cash and technology at $1.75 per share.
Maxim Group
Jason McCarthy
Strong Buy
to
Hold
Downgrades
n/a
2025-03-25
Reason
Maxim Group
Jason McCarthy
Price Target
n/a
2025-03-25
Downgrades
Strong Buy
to
Hold
Reason
Maxim analyst Jason McCarthy downgraded CNS Pharmaceuticals to Hold from Buy after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.
See All Ratings

Valuation Metrics

The current forward P/E ratio for CNS Pharmaceuticals Inc (CNSP.O) is -0.45, compared to its 5-year average forward P/E of -2.88. For a more detailed relative valuation and DCF analysis to assess CNS Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.88
Current PE
-0.45
Overvalued PE
4.52
Undervalued PE
-10.29

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CNSP News & Events

Events Timeline

(ET)
2025-11-17
08:55:38
CNS Pharmaceuticals anticipates funding to last through the second half of 2026.
select
2025-11-17
08:55:22
CNS Pharmaceuticals Announces Q3 EPS of $5.76 Compared to ($153.20) in the Previous Year
select
2025-08-15 (ET)
2025-08-15
08:06:59
CNS Pharmaceuticals sees cash runway into 2H26
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
09-16Benzinga
Webtoon Entertainment Shares Surge 48%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Webtoon Entertainment Partnership: Webtoon Entertainment Inc's shares surged 47.8% in pre-market trading after announcing a partnership with The Walt Disney Co to create a digital comics platform featuring Marvel, Star Wars, Pixar, and Disney titles.

  • Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, with FGI Industries Ltd gaining 185.2% and Conifer Holdings Inc rising 136.8%, while Apartment Investment and Management Company saw a decline of 9.4%.

[object Object]
Preview
4.0
09-13Yahoo Finance
CNS Pharmaceuticals Receives Buy Rating from Maxim Following TPI-287 Development Plan

  • CNS Pharmaceuticals Upgrade: Maxim upgraded CNS Pharmaceuticals from Hold to Buy with a price target of $20, highlighting the company's focus on its oncology asset TPI-287 for treating recurrent glioblastoma.

  • Financial Outlook: The analyst noted CNS Pharmaceuticals' roadmap for TPI-287, potential developments with Berubicin, and a cash runway extending into the second half of 2026, indicating a positive outlook for the stock's recovery.

[object Object]
Preview
9.0
08-27Newsfilter
IBN Unveils New Episode of The BioMedWire Podcast with CNS Pharmaceuticals Inc. CEO John Climaco

  • Podcast Release: IBN has released a new episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals, discussing advancements in treatments for brain cancer.

  • CNS Pharmaceuticals Focus: The company is dedicated to developing novel therapies for glioblastoma and other cancers that affect the brain and central nervous system, addressing significant unmet medical needs.

  • Drug Development Strategy: CNS Pharmaceuticals has successfully pivoted from its berubicin study to focus on TPI 287, demonstrating resilience in drug development despite high failure rates in oncology trials.

  • Market Potential: Climaco highlighted the vast opportunities for their drugs in various cancer markets, emphasizing the company's operational expertise and commitment to advancing treatment options for patients.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CNS Pharmaceuticals Inc (CNSP) stock price today?

The current price of CNSP is 6.51 USD — it has decreased -2.25 % in the last trading day.

arrow icon

What is CNS Pharmaceuticals Inc (CNSP)'s business?

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

arrow icon

What is the price predicton of CNSP Stock?

Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CNS Pharmaceuticals Inc (CNSP)'s revenue for the last quarter?

CNS Pharmaceuticals Inc revenue for the last quarter amounts to -3.25M USD, decreased -42.20 % YoY.

arrow icon

What is CNS Pharmaceuticals Inc (CNSP)'s earnings per share (EPS) for the last quarter?

CNS Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for CNS Pharmaceuticals Inc (CNSP)'s fundamentals?

The market is revising No Change the revenue expectations for CNS Pharmaceuticals, Inc. (CNSP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.17%.
arrow icon

How many employees does CNS Pharmaceuticals Inc (CNSP). have?

CNS Pharmaceuticals Inc (CNSP) has 4 emplpoyees as of December 05 2025.

arrow icon

What is CNS Pharmaceuticals Inc (CNSP) market cap?

Today CNSP has the market capitalization of 4.04M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free